organization · Reporting owner

ALAFI CAPITAL CO LLC

Disclosed activity across 2 companies

Tapewire entity: 20293
SEC CIK: 0001216017

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CalciMedica, Inc.CALC · Entity 7804	10% owner	August 19, 2026	August 24, 2026
Intra-Cellular Therapies, Inc.ITCI · Entity 81206	10% owner	October 02, 2017	October 03, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CalciMedica, Inc.

Report date August 19, 2026 · Filed August 24, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Series A WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.80	Direct	3,529,192	Reported balance After 2026-08-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-08-19 · Grant · Acquired 3,529,192 · Balance 3,529,192 F1: The issue date of the Series A Warrants is August 19, 2026. F2: The expiration of these Series A Warrants is the earlier of (i) 18 months after the closing date of the Private Placement and (ii) 30 days following the Issuer's public announcement of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480.
Series B WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2031-06-23	Direct	3,529,192	Reported balance After 2026-08-19 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-08-19 · Grant · Acquired 3,529,192 · Balance 3,529,192 F3: The issue date of the Series B Warrants is August 19, 2026.
Common StockSEC Table I · non-derivative	Direct	5,112,345	Reported balance Holding disclosure · report date 2026-08-19 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 5,112,345

Filing footnotes · ownership attribution and instrument terms

F1: The issue date of the Series A Warrants is August 19, 2026.

F2: The expiration of these Series A Warrants is the earlier of (i) 18 months after the closing date of the Private Placement and (ii) 30 days following the Issuer's public announcement of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480.

F3: The issue date of the Series B Warrants is August 19, 2026.

Intra-Cellular Therapies, Inc.

Report date October 02, 2017 · Filed October 03, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,953,270	Reported balance After 2017-10-02 transaction · row 1 1 source row Row 1 · 2017-10-02 · Purchase · Acquired 258,065 · Balance 3,953,270

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 19, 2026 Filed Aug 24, 2026 21:03 UTC	CalciMedica, Inc. CALC · Entity 7804	GrantSeries B Warrants · Derivative	3,529,192	$0.00 Strike: $1.00	$0.00	Disclosure SEC source: 0000912282-26-001157 · form4.xml · derivative · entry 3 ALAFI CAPITAL CO LLC · CIK 0001216017 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,529,192 Underlying: Common Stock · 3,529,192 shares Expires 2031-06-23 F3 · derivative.exercise_date: The issue date of the Series B Warrants is August 19, 2026. Read SEC document
August 19, 2026 Filed Aug 24, 2026 21:03 UTC	CalciMedica, Inc. CALC · Entity 7804	GrantSeries A Warrants · Derivative	3,529,192	$0.00 Strike: $0.80	$0.00	Disclosure SEC source: 0000912282-26-001157 · form4.xml · derivative · entry 2 ALAFI CAPITAL CO LLC · CIK 0001216017 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,529,192 Underlying: Common Stock · 3,529,192 shares Expires not disclosed F1 · derivative.exercise_date: The issue date of the Series A Warrants is August 19, 2026. F2 · derivative.expiration_date: The expiration of these Series A Warrants is the earlier of (i) 18 months after the closing date of the Private Placement and (ii) 30 days following the Issuer's public announcement of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480. Read SEC document
October 02, 2017 Filed Oct 3, 2017 22:08 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	PurchaseCommon Stock	258,065	$15.50	$4,000,007.50	Disclosure SEC source: 0001209191-17-055362 · doc4.xml · nonDerivative · entry 1 ALAFI CAPITAL CO LLC · CIK 0001216017 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,953,270 Read SEC document
December 07, 2016 Filed Dec 7, 2016 21:21 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	PurchaseCommon Stock	20,826	$16.14	$336,037.92	Disclosure SEC source: 0001209191-16-153891 · doc4.xml · nonDerivative · entry 2 ALAFI CAPITAL CO LLC · CIK 0001216017 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,695,205 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.91 to $16.37 per share, inclusive. Read SEC document
December 06, 2016 Filed Dec 7, 2016 21:21 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	PurchaseCommon Stock	44,174	$16.33	$721,445.35	Disclosure SEC source: 0001209191-16-153891 · doc4.xml · nonDerivative · entry 1 ALAFI CAPITAL CO LLC · CIK 0001216017 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,674,379 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.28 to $16.50 per share, inclusive. Read SEC document
November 14, 2016 Filed Nov 17, 2016 21:34 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	PurchaseCommon Stock	34,000	$14.50	$492,969.40	Disclosure SEC source: 0001209191-16-150884 · doc4.xml · nonDerivative · entry 1 ALAFI CAPITAL CO LLC · CIK 0001216017 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,630,205 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.41 to $14.50, inclusive. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.